Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism

Journal of Bone and Mineral Research

Volumn 16, Issue 1, 2001, Pages 113-119

  Rossini, Maurizio ^a   Gatti, Davide ^a   Isaia, Giancarlo ^b   Sartori, Leonardo ^c   Braga, Vania ^a   Adami, Silvano ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Alendronate; Bisphosphonates; Osteoporosis; Primary hyperparathyroidism

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM; DEOXYPYRIDINOLINE; OSTEOCALCIN; PHOSPHATE;

AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; AMINO ACIDS; BONE DENSITY; CALCIUM; CREATININE; DENSITOMETRY, X-RAY; FEMALE; FEMUR; HUMANS; HYPERPARATHYROIDISM; OSTEOCALCIN; OSTEOPOROSIS; PARATHYROID HORMONE; PHOSPHATES; PILOT PROJECTS; RANDOM ALLOCATION; RETROSPECTIVE STUDIES;

EID: 0035163394     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2001.16.1.113     Document Type: Article

References (43)

1. Back pain and vertebral crush fractures: An unemphasized mode of presentation for primary hyperparathyroidism
2. What is the clinical significance of bone loss in primary hyperparathyroidism?
3. Primary hyperparathyroidism and the risk of fracture: A population-based study
4. Increased bone mineral density following parathyroidectomy in primary hyperparathyroidism
5. Vertebral osteopenia: A new indication for surgery in primary hyperparathyroidism
6. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism
7. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery
8. Primary hyperparathyroidism: Short-term changes in bone remodeling and bone mineral density following parathyroidectomy
9. Primary hyperparathyroidism: Effect of parathyroidectomy on regional bone mineral density in Danish patients: A three year follow up study
10. Primary hyperparathyroidism: Whole-body bone mineral density in surgically treated Danish patients: A three-year follow-up study
11. Diagnosis and management of asymptomatic hyperparathyroidism: Consensus development conference statement
12. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism
13. Estrogens and progestins in the management of primary hyperparathyroidism
14. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women
15. Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy
16. Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: A preliminary report
17. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial
18. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism
19. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism
20. Drug treatment of primary hyperparathyroidism: Use of clodronate disodium
21. Clodronate in the medical management of hyperparathyroidism
22. Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: Effect on clinical status
23. Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: Effects of bisphosphonate treatment
24. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone
25. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate
26. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
27. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
28. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures
29. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
30. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis
31. For the Alendronate Once-Weekly Study Group 2000 Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
32. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
33. Dose-response relationships for alendronate treatment in osteoporotic elderly women
34. Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment
35. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis
36. Increased fracture risk in hypercalcemia: Bone mineral content measured in hyperparathyroidism
37. The risk of hip fractures in patients with primary hyperparathyroidism: A population-based cohort study with a follow-up of 19 years
38. Risk of age-related fractures in patients with primary hyperparathyroidism
39. Fracture incidence in postmenopausal women with primary hyperparathyroidism
40. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures
41. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism
42. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: Evidence for biphasic disease course
43. Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: Clinical course and considerations bearing on the need for surgical intervention